fashion -WSS

fashion

author：hotspot 2025-08-28 13:07:27 - browse：13992

A caretaker speaks with an elderly Alzheimer's patient at a nursing home. — ALAIN JOCARD/AFP via Getty Images

For more than 30 years, Alzheimer’s researchers have thought of APOE4 as a major genetic risk factor for most cases of the devastating neurologic disease. But a new study published on Monday argues that this gene variant plays an even more important role than scientists had realized and causes a distinct form of Alzheimer’s.

Researchers analyzed data from more than 13,000 people, including nearly 800 APOE4 homozygotes, people who carry two copies of the gene variant. They found that nearly all of the homozygotes showed biological signs of Alzheimer’s in the brain, and they typically developed dementia and other symptoms, and died sooner, than people with Alzheimer’s who lack APOE4.

The research team also found that APOE4 homozygotes showed a predictable pattern of biomarker changes linked to Alzheimer’s, including a buildup of beta-amyloid and tau, a protein linked to neuron damage and death.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： First Opinion Podcast: How to protect health care in times of war

WSS

Diversifying clinical trials isn't enough to close racial gaps: study

Hospitals warn Medicare's drug payment fix is ‘unlawful’

The pink breast cancer awareness ribbon needs a redesign

At ASCO, AstraZeneca reports strong data for breast cancer drug

Diversifying clinical trials isn't enough to close racial gaps: study

The FDA weighs the risks of candy

leisure time

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

entertainment

State Dept. review finds Biden bears some blame for Afghanistan failures

The FDA weighs the risks of candy

Wildfire smoke exposes gaps in outdoor worker protections

Eli Lilly to pay $200M for Beam’s stake in gene

23andMe had bad news about my health. I wish a person had delivered it

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Medicare details structure of new drug price negotiation program

Senate panel to vote on hospitals, PBMs, prisoner care

Apple is now the first public company to be valued at $3 trillion

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

entertainment

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

The pink breast cancer awareness ribbon needs a redesign

Chimpanzees, like humans and whales, get menopause: Study

How to increase colonoscopy rates? Looks like an AI can help

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

focus

explore

knowledge

hotspot